

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

## Blincyto (blinatumomab)

Override(s)	Approval Duration
Prior Authorization	1 Year

Medications
Blincyto (blinatumomab)

### APPROVAL CRITERIA

Requests for Blincyto (blinatumomab) may be approved if the following criteria are met:

- I. Individual has a diagnosis CD19+B-cell precursor acute lymphocytic leukemia (ALL); **AND**
- II. Blinatumomab is used as a single agent; **AND**
- III. Individual is using for one of the following:
  - A. Relapsed or refractory disease; **OR**
  - B. Minimal residual disease greater than or equal to 0.1%, following a first or second complete response to induction therapy.

Requests for Blincyto (blinatumomab) may not be approved for the following:

- I. All other indications not included above; **OR**
- II. Individual has evidence of active ALL central nervous system involvement; **OR**
- III. Use as first-line of therapy for ALL; **OR**
- IV. Use in combination with other chemotherapy agents; **OR**
- V. Treatment of diffuse large B-Cell lymphoma (DLBCL).

State Specific Mandates		
State Name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

### Key References:

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
<b>Applicable</b>	X	X	X	X	X	X	X

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2018. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: June 14, 2019.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.
5. NCCN Clinical Practice Guidelines in Oncology™. © 2019 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on March 27, 2019.
  - a. Acute Lymphoblastic Leukemia. V1.2018. Revised March 12, 2018.
  - b. B-Cell Lymphomas. V2.2019. Revised March 6, 2019.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.